GET DAILY SIGNALSAscendis Pharma (ASND): Can It Hit the +21% Upside to the $310 Analyst Target?
Key Takeaways
- The central target is $310, calculated as the arithmetic mean of 17 verified analyst price targets, rounded to a clean level.
- The latest verified close is $256.59 (Nov. 10, 2026), meaning the stock would need to rise roughly 21% to reach $310.
- Individual targets range from a low of $268 (Canaccord Genuity) to a high of $344 (H.C. Wainwright), a wide spread that signals genuine disagreement about valuation.
- The strongest supporting factors are accelerating revenue growth, the Yorvipath commercial ramp, a BioMarin royalty settlement, and a $400 million buyback.
- The biggest risks are pipeline setbacks, the Novo Nordisk decision to return TransCon rights, valuation compression, and launch execution.
- The $310 target is a reference point, not a guarantee, and reflects roughly a 12-month research horizon.
- For more on this company's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for each.
- Discover actionable trade ideas by exploring Trending AI Robots.
Understanding the Analyst Consensus on ASND
ASND is a Danish biopharmaceutical company whose American Depositary Receipts trade on Nasdaq. It develops therapies using its TransCon technology platform for rare endocrine diseases. Its lead commercial products are Skytrofa for growth hormone deficiency, Yorvipath for hypoparathyroidism, and Yuviwel for achondroplasia.
Looking across 17 individually attributed analyst price targets from named firms and dated within recent months produces an arithmetic mean of about $310.29, which rounds cleanly to the $310 central target. The range remains wide, with Canaccord Genuity starting coverage at a $268 Hold and H.C. Wainwright holding a $344 Buy. The broader Street view stays constructive overall, with most ratings at Buy or equivalent and just one Hold and no Sell ratings in the recent period.
Bullish targets generally factor in sustained Yorvipath growth and pipeline progress, while more cautious ones account for execution risks and a narrower innovation outlook after certain partner exits. TD Cowen reiterated at $341, Citi at $330, and Jefferies at $330, while Morgan Stanley sits lower at $273. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path to the Target
At the latest close of $256.59, reaching $310 would require an upside of about 20.8%. The share price sits within a 52-week range of $188.07 to $282.15, so the target sits above the prior peak. Any move toward $310 would likely need a sustained break above the $282 area first.
Fundamentals are strengthening. Street estimates point to revenue of roughly $1.37 billion for 2026, up about 90% from 2025, with Yorvipath net sales expected to exceed $1.1 billion this year. The normalized P/E ratio stands around 20 and the price-to-sales ratio near 13, levels that price in growth without appearing extreme for a profitable rare-disease biotech. From what I see, these multiples remain reasonable given the trajectory.
Factors That Could Support a Move Toward $310
- Commercial momentum: Yorvipath’s launch ramp and Yuviwel’s U.S. uptake are the primary value drivers cited by analysts.
- BioMarin settlement: A royalty settlement cleared a legal overhang and provided freedom to operate for Yuviwel.
- Capital returns: A $400 million share buyback and strong operating cash flow signal financial strength and management confidence.
- Earnings execution: A roughly 104% EPS beat in the second quarter reinforced a profitability inflection.
- Analyst support: Recent target hikes from firms including TD Cowen, Citi, and Oppenheimer reflect constructive model updates.
Risks That Could Keep the Target Out of Reach
- Pipeline disappointment: Novo Nordisk’s decision to return TransCon rights, following earlier partner exits, has pressured sentiment on the innovation story.
- Valuation compression: With a price-to-sales ratio near 13, any slowdown in growth could trigger multiple contraction.
- Launch execution: Slower-than-expected Yorvipath or Yuviwel adoption would undercut revenue forecasts.
- Competition and regulation: Rare-disease markets remain competitive, and pricing or reimbursement changes pose ongoing risks.
Technical Levels and Market Structure
The most durable technical reference is the 52-week high near $282, which has acted as resistance. A close above that level would be a meaningful structural signal for bulls. On the downside, the round-number $250 area has provided support in recent sessions, and the $188 low marks the broader risk zone. The long-term structure remains in an uptrend off the 2025 lows, but the stock has yet to establish a decisive breakout above prior highs. I’m watching this closely around those key levels.
Time Horizon and What to Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms may differ, and the target is not a timed forecast. Investors should watch quarterly results, Yorvipath and Yuviwel sales trends, any new TransCon data or partnership updates, analyst revisions, the progress of the buyback, and broader biotech sector conditions. A decisive break above $282 or a slip below $250 would reframe the technical setup.
Final Assessment
Whether ASND can reach $310 depends on execution more than sentiment. The roughly 21% move would require a breakout above the $282 prior high, continued Yorvipath and Yuviwel growth, and renewed confidence in the TransCon pipeline. The $268 to $344 analyst range shows that even constructive analysts disagree sharply on the pace and durability of growth. The $310 central target is best understood as an aggregate of reasonable outcomes, not a forecast, and investors should monitor commercial launches, pipeline news, and the stock’s behavior around key technical levels before drawing conclusions.
Using Tickeron’s AI Daily Buy/Sell Signals for Additional Perspective
In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a systematic view of momentum. The tool applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps users discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening alone. This approach has become a useful complement to traditional research when evaluating names like ASND.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ASND's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ASND turned positive on October 09, 2026. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in 45 of 56 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on ASND as a result. In 68 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
ASND moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ASND crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.
Following a +2.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in 183 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 97 of 126 cases where ASND Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for ASND moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
ASND broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 45 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.761) is normal, around the industry mean (3.498). P/E Ratio (21.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.970) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drug candidates
Industry Biotechnology
Advertisement